Summary of clinical histories of basal-like tumours responding to chemotherapy
| Case number | Disease-free survival (months) | Relapse site | Treatment after relapse of disease | Response | Time from response to PD (months) | Site of PD | Treatment at progression | Time from relapse to death (months) |
|---|---|---|---|---|---|---|---|---|
| 5-FU, 5-fluorouracil; CT, computed tomography; DXT, radiotherapy; FTI, farnesyl transferase inhibitor; LN, lymph nodes; MVP, mitomycin, vinblastine, cisplatin; PD, progressive disease; PR, partial response; US, ultrasound. | ||||||||
| 1 | 19 | Bone, LN | MVP 6 cycles DXT (bone) | PR (post cycle 3 and 6, CT) | 6 | Breast LN | Doxorubicin (4 cycles) | 17 |
| 2 | 20 | Bone, liver | Doxorubicin 6 cycles | PR (post cycle 3 and 6, CT) | NA | NA | NA | 5 |
| 3 | 24 | Ipsilateral breast | Neoadjuvant vinorelbine | PR post 2 cycles PD post 4 cycles (clinical) | 1 | Chest wall, LN | Letrozole 2 months PD docetaxel (6 cycles) PD liver, sternum, pleural effusion capecitabine 2 months | 35 |
| 4 | 12 | LN neck, axilla | Surgery DXT PD on treatment docetaxel 4 cycles | PR (post 2 cycles, US) | 2 | LN | FTI 3 months PD chest wall vinorelbine+5FU (2 cycles) PD chest wall, LN MVP (7 cycles) PD lung | 14 |